Nanobiotix stock breaks through 27.94 € support level, lagging the SBF 120 index
The oncological nanomedicine biotech stock experienced the steepest decline on the broader index on Monday morning, breaching a key technical threshold in the process. This latest pullback is part of a particularly heavy monthly sequence, although the stock still maintains an exceptional twelve-month gain.
Support broken during the session with three moving averages above the price
Nanobiotix is down 6.17% at 27.36 € during the session, the weakest performer on the SBF 120, which itself is trading practically flat (+0.12%). The stock has broken through its 27.94 € support level during the session and remains below it (last price at 27.36 €), which now places all moving average benchmarks above the current price. The 200-day moving average at 28.51 € is 4% above the price, while the 20-day MA (31.57 €) and 50-day MA (33.29 €) are respectively 13.3% and 17.8% higher.
This configuration, where the stock finds itself below all three moving averages following a brutal September, reflects diffuse selling pressure: the monthly decline reaches 29.12% and the weekly loss stands at 8.37%. The RSI at 40 remains in neutral territory but is approaching levels that had preceded brief rebounds in the stock in recent weeks. The next identified resistance level is located at 38.60 €, over 40% above the current price.
Cash position of 110.9 M€ secured until 2029, but annual gains eroding
Despite this technical setback, the fundamental profile of Nanobiotix was clarified during the publication of the half-yearly update on September 24, 2026: the biotech reported a cash position of 110.9 M€ at that time, an amount deemed sufficient to finance its operations through 2029. This financial flexibility resulted from a capital increase of approximately 86 M€ completed in May 2026, which boosted the cash position from 52.8 M€ at the end of December 2025 to its current level. To read, detailed half-yearly results.
Over twelve months, the stock still maintains a gain of 107.9%, but this cushion is diminishing as the September correction extends: the quarterly decline reaches 11.97%, and the current month's downward sequence is erasing a significant portion of annual performance. The radio-amplifier NBTXR3 (JNJ-1900), developed in partnership with Johnson & Johnson, represents the company's primary clinical asset, with phase 1 data published on September 14, 2026 showing a one-year locoregional control rate of 79% in non-small cell lung cancer. The 38.60 € resistance level stands out as the next key graphic benchmark to monitor.
